<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1208245753
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PLUVICTO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LUTETIUM 177LU VIPIVOTIDE TETRAXETAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        MBq/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Radiopharmaceutical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        0.17
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        100266.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Advanced Accelerator Applications" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Advanced Accelerator Applications
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V10XX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Pluvicto is</strong></p><p>Pluvicto contains lutetium (<sup>177</sup>Lu) vipivotide tetraxetan. This medicine is a radiopharmaceutical product for therapy only.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>What Pluvicto is used for</strong></p><p>Pluvicto is used to treat adults with progressive castration‑resistant prostate cancer that has spread to other parts of the body (metastatic) and has already been treated with other cancer treatments. Castration‑resistant prostate cancer is a cancer of the prostate (a gland of the male reproductive system) that does not respond to treatment that reduces male hormones. Pluvicto is used if the prostate cancer cells have a protein on their surface called prostate‑specific membrane antigen (PSMA).</p><p><strong>How Pluvicto works</strong></p><p>Pluvicto binds to PSMA found on the surface of the prostate cancer cells. Once bound, the radioactive substance in Pluvicto, lutetium‑177, gives off radiation that causes the prostate cancer cells to die.</p><p>Your doctor will carry out tests to see if PSMA is present on the surface of the cancer cells. Your cancer is more likely to respond to treatment with Pluvicto if the test result is positive.</p><p>The use of Pluvicto involves exposure to amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweighs the risk due to radiation.</p><p>If you have any questions about how Pluvicto works or why this medicine has been prescribed for you, ask your nuclear medicine doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given by your nuclear medicine doctor carefully. They may differ from the general information contained in this leaflet.</p><p><strong>a. Do not use Pluvicto</strong></p><p>- if you are allergic to lutetium (<sup>177</sup>Lu) vipivotide tetraxetan or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p><strong>b. Take special care with Pluvicto</strong></p><p>If any of these apply to you, tell your nuclear medicine doctor before receiving Pluvicto:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low levels of certain types of cells in the blood (red blood cells, white blood cells, neutrophils, platelets)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or bleeding for longer than normal, or frequent infections with signs such as fever, chills, sore throat or mouth ulcers (possible signs of myelosuppression [a condition in which the bone marrow cannot make enough blood cells])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had any other type of cancer or treatment for cancer, as Pluvicto contributes to your overall long‑term cumulative radiation exposure</p><p><strong>Before administration of Pluvicto you should:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink plenty of water so that you remain hydrated and urinate as often as possible during the first hours after administration</p><p><strong>&nbsp;</strong></p><p><strong>c. Children and adolescents</strong></p><p>The safety and efficacy of this medicine have not been established in children and adolescents under 18&nbsp;years of age. This medicine should not be given to children or adolescents aged under 18&nbsp;years because no data are available in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>d. Pregnancy and breast-feeding</strong></p><p><u>Pregnancy</u></p><p>Pluvicto is not intended for use in women.</p><p>Before you receive Pluvicto, tell your nuclear medicine doctor if you are sexually active as all radiopharmaceuticals, including Pluvicto, have the potential to cause harm to an unborn baby.</p><p><u>Fertility</u></p><p>Pluvicto may cause infertility. Please ask your nuclear medicine doctor how this may affect you, especially if you are planning to have children in the future. You may wish to seek advice on preservation of sperm before treatment starts.</p><p><u>Contraception in males</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should avoid sexual activity for 7&nbsp;days after administration of Pluvicto.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not father a child and should use a condom during intercourse throughout treatment with Pluvicto and for 14&nbsp;weeks after your last dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your nuclear medicine doctor immediately if you father a child at any time during this time period.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>e. Driving and using machines</strong></p><p>It is considered unlikely that Pluvicto will affect your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>f. Important information about some of the ingredients of Pluvicto</strong></p><p><strong>Pluvicto contains sodium</strong></p><p>This medicine contains up to 88.75 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 4.4% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>There are strict laws on the use, handling and disposal of radiopharmaceutical products. Pluvicto will only be used in special controlled areas. This radiopharmaceutical product will only be handled and given to you by people who are trained and qualified to use it safely. These persons will take special care for the safe use of this radiopharmaceutical product and will keep you informed of their actions.</p><p><strong>How much Pluvicto is given</strong></p><p>The recommended treatment regimen of Pluvicto is 7 400 MBq (megabecquerel, the unit used to express radioactivity), which is given approximately every 6 weeks for up to a total of 6 doses.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Administration of Pluvicto and conduct of the procedure</strong></p><p>Pluvicto is administered directly into a vein.</p><p><strong>&nbsp;</strong></p><p><strong>Duration of the procedure</strong></p><p>Your nuclear medicine doctor will inform you about the usual duration of the procedure.</p><p>&nbsp;</p><p>If you have questions about how long you will receive Pluvicto, talk to your nuclear medicine doctor.</p><p>&nbsp;</p><p><strong>Treatment monitoring</strong></p><p>Your nuclear medicine doctor will do blood tests before and during treatment to check your condition and to detect any side effects as early as possible. Based on the results, your nuclear medicine doctor may decide to delay, change or stop your treatment with Pluvicto if necessary.</p><p><strong>&nbsp;</strong></p><p><strong>After administration of Pluvicto, you should:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink plenty of water for 2&nbsp;days so that you remain hydrated and urinate as often as possible to eliminate the radiopharmaceutical product from your body</p><p>&nbsp;</p><p>Because this medicine is radioactive, you will have to follow the instructions described below to minimise radiation exposure to others unless otherwise instructed by your nuclear medicine doctor.</p><p>&nbsp;</p><p><u>Contact with others in your household, children, and/or pregnant women</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Limit close contact (less than 1&nbsp;metre) with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; others in your household for 2&nbsp;days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children and pregnant women for 7&nbsp;days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep in a separate bedroom from:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; others in your household for 3&nbsp;days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children for 7&nbsp;days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pregnant women for 15&nbsp;days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid sexual activity for 7&nbsp;days</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not father a child and do use a condom during intercourse throughout treatment with Pluvicto and for 14&nbsp;weeks after your last dose</p><p>&nbsp;</p><p><u>Use of toilets</u></p><p>Take special precautions to avoid contamination for 2&nbsp;days after administration:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must always sit when using the toilet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is essential that you use toilet paper every time you use the toilet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always wash your hands well after using the toilet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flush all wipes and/or toilet paper down the toilet immediately after use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flush any tissues or any other items that contain bodily waste, such as blood, urine and faeces down the toilet. Items that cannot be flushed down the toilet, such as bandages, must be placed in separate plastic waste disposal bags (according to &ldquo;Waste disposal recommendations&rdquo; below).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any special medical equipment that could be contaminated by your bodily fluids (e.g. catheter bags, colostomy bags, bedpans, water nozzles) must be emptied immediately into the toilet and then cleaned.</p><p><u>&nbsp;</u></p><p><u>Showering and laundry</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take a shower every day for at least 7&nbsp;days after administration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your underwear, pyjamas, sheets and any clothes that contain sweat, blood or urine separately from the laundry of others in your household, using a standard washing cycle. You do not need to use bleach and you do not need extra rinses.</p><p>&nbsp;</p><p><u>Care givers</u></p><p>For 2‑3&nbsp;days after administration:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People who are confined to bed or have reduced mobility will preferably receive assistance from a care giver. It is recommended that when providing assistance in the bathroom, the care giver wears disposable gloves.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Care givers who clean up vomit, blood, urine or faeces should wear plastic gloves, which should be disposed of in a separate plastic waste disposal bag (see &ldquo;Waste disposal recommendations&rdquo; below).</p><p>&nbsp;</p><p><u>Waste disposal recommendations</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All items to be thrown away should be discarded in a separate plastic waste disposal bag to be used only for this purpose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the plastic waste disposal bags separate from the other household waste and away from children and animals.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A member of the hospital staff will tell you how and when to get rid of these waste disposal bags.</p><p>&nbsp;</p><p><u>Hospitalisation and emergency care</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If for any reason you require emergency medical assistance or are unexpectedly admitted to the hospital during the first 7&nbsp;days after administration, you should inform the healthcare professionals about the name, date and dose of your radioactive treatment.</p><p>&nbsp;</p><p><u>Other precautions</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The nuclear medicine doctor will inform you if you need to take any other special precautions after receiving this medicine. Contact your nuclear medicine doctor if you have any questions.</p><p>&nbsp;</p><p><strong>a.If you have been given more Pluvicto than you should</strong></p><p>An overdose is unlikely because you will only receive Pluvicto in doses that are precisely controlled by the nuclear medicine doctor supervising the procedure. However, in the event of an overdose, you will receive the appropriate treatment.</p><p><strong>b.If you forget to receive Pluvicto</strong></p><p>If you miss an appointment to receive Pluvicto, contact your nuclear medicine doctor as soon as possible to reschedule.</p><p>Should you have any further questions on the use of Pluvicto, please ask the nuclear medicine doctor who supervises the procedure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects could be serious</strong></p><p>If you experience any of the following serious side effects, <strong>tell your nuclear medicine doctor right away.</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, weakness, pale skin or shortness of breath (possible signs of low levels of red blood cells [<em>anaemia</em>])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding or bruising more easily than normal or bleeding for longer than normal (possible signs of low levels of platelets [<em>thrombocytopenia</em>])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequent infections with signs such as fever, sore throat or mouth ulcers (possible signs of low levels of white blood cells [<em>leukopenia, lymphopenia</em>])</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in every 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; passing urine less often or in much smaller amounts than usual (possible sign of kidney problems [<em>acute kidney injury</em>])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or bleeding for longer than normal or frequent infections with signs such as fever, chills, sore throat or mouth ulcers (possible signs of low levels of blood cells [<em>pancytopenia</em>])</p><p><strong>&nbsp;</strong></p><p><strong>Other possible side effects</strong></p><p>Other side effects include the following listed below. If these side effects become severe, please tell your nuclear medicine doctor.</p><p>&nbsp;</p><p><strong>Very common:</strong> may affect more than 1 in 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (<em>fatigue</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in bowel movements (<em>constipation or diarrhoea</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequent urination with pain or burning sensation (<em>urinary tract infection</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in every 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles or feet (<em>peripheral oedema</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed sense of taste (<em>dysgeusia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (<em>pyrexia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, with a spinning sensation (<em>vertigo</em>)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulations on radioactive materials.</p><p>The following information is intended for the specialist only:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from ionising radiation (lead shielding).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pluvicto must not be used after the expiry date and time which are stated on the lead shielding container and vial labels after EXP.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicine or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. What Pluvicto contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lutetium (<sup>177</sup>Lu) vipivotide tetraxetan. One mL of solution contains 1&nbsp;000&nbsp;MBq lutetium (<sup>177</sup>Lu) vipivotide tetraxetan at the date and time of calibration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: acetic acid, sodium acetate, gentisic acid, sodium ascorbate, pentetic acid, water for injections (see &ldquo;Pluvicto contains sodium&rdquo; in section&nbsp;2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pluvicto is a clear, colourless to slightly yellow solution supplied in a clear, colourless type I glass vial, closed with a bromobutyl rubber stopper and aluminium seal.
Each vial contains a volume of solution that can range from 7.5 mL to 12.5 mL corresponding to a radioactivity of 7 400 MBq ±10% at the date and time of administration.
The vial is enclosed within a lead container for protective shielding.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The marketing Authorization holder for this product is Novartis Europharm Limited,Ireland</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved / revised by EMA in 12/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو بلوفيكتو</strong></p><p dir="RTL">يحتوي بلوفيكتو على اللوتيشيوم (<sup>177</sup>Lu) فيبيفوتايد تتراكسيتان. هذا الدواء هو منتج دوائي إشعاعي مخصص للعلاج فقط.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>دواعي استعمال بلوفيكتو</strong></p><p dir="RTL">يُستخدم بلوفيكتو لعلاج البالغين المصابين بسرطان البروستاتا المتقدم المقاوم للإخصاء، والذي انتشر إلى أجزاء أخرى من الجسم (نقيلي)، وعُولج بالفعل بعلاجات أخرى للسرطان. سرطان البروستاتا المقاوم للإخصاء هو سرطان في البروستاتا (غدة&nbsp;في الجهاز التناسلي الذكري) لا يستجيب للعلاج الذي يقلل الهرمونات الذكورية. يُستخدم بلوفيكتو إذا كانت خلايا سرطان البروستاتا تحتوي على بروتين على سطحها يُسمى مستضد غشاء البروستات النوعي (PSMA).</p><p dir="RTL"><strong>آلية عمل بلوفيكتو</strong></p><p dir="RTL">يلتصق بلوفيكتو بمستضد غشاء البروستات النوعي الموجود على سطح خلايا سرطان البروستاتا. بمجرد التصاق بلوفيكتو بهذا المستضد، تُطلق المادة المشعة الموجودة في بلوفيكتو، وهي عنصر اللوتيشيوم 177، إشعاعًا يتسبب في موت خلايا سرطان البروستاتا.</p><p dir="RTL">سيُجري طبيبك اختبارات لمعرفة ما إذا كان مستضد غشاء البروستات النوعي موجودًا على سطح الخلايا السرطانية. من&nbsp;المرجح أن يستجيب السرطان لديك للعلاج بعقار بلوفيكتو إذا كانت نتيجة الاختبار إيجابية.</p><p dir="RTL">ينطوي استخدام بلوفيكتو على التعرّض لكميات من النشاط الإشعاعي. لقد اعتبر طبيبك وطبيب الطب النووي المتابع لك أن الفائدة السريرية التي ستحصل عليها من الإجراء الذي يتم باستخدام الدواء المُشع تفوق المخاطر الناجمة عن الإشعاع.</p><p dir="RTL">إذا كانت لديك أي أسئلة حول آلية عمل بلوفيكتو أو سبب وصف هذا الدواء لك، فاطرحها على طبيب الطب النووي المتابع لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع جميع التعليمات التي يعطيها لك طبيب الطب النووي المتابع لك بدقة. فقد تختلف عن المعلومات العامة الواردة في هذه النشرة.</p><p dir="RTL"><strong>أ. موانع استعمال بلوفيكتو</strong></p><p dir="RTL">- إذا كانت لديك حساسية تجاه مادة اللوتيشيوم (<sup>177</sup>Lu) فيبيفوتايد تتراكسيتان أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>ب. احتياطات استخدام بلوفيكتو</strong></p><p dir="RTL">إذا انطبق عليك أي مما يلي، فأخبر طبيب الطب النووي المتابع لك قبل استخدام بلوفيكتو:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مستويات منخفضة من أنواع معينة من الخلايا في الدم (خلايا الدم الحمراء، وخلايا الدم البيضاء، والعدلات، والصفائح الدموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من تعب أو ضعف أو شحوب الجلد أو ضيق في التنفس أو النزف أو التكدم بسهولة تفوق المعتاد أو النزف لفترة أطول من المعتاد أو حالات عدوى متكررة مصحوبة بعلامات مثل الحمّى أو القشعريرة أو التهاب الحلق أو قرح الفم (علامات محتملة على الإصابة بكبت النقي [حالة لا يستطيع فيها نخاع العظم إنتاج كميات كافية من خلايا الدم])</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من مشكلات في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت من أي نوع آخر من السرطان أو كنت تخضع أو قد خضعت لعلاج للسرطان، حيث إن بلوفيكتو يساهم في تعرضك للإشعاع التراكمي الكلي طويل الأجل</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل إعطاء بلوفيكتو، يجب عليك:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرب الكثير من الماء للحفاظ على ترطيب جسمك والتبول قدر الإمكان خلال الساعات الأولى بعد تلقي بلوفيكتو</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج. الأطفال والمراهقون</strong></p><p dir="RTL">لم تثبت سلامة هذا الدواء وفعاليته لدى الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا. يجب عدم إعطاء هذا الدواء للأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا لأنه لا تتوفر بيانات من هذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د. الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">بلوفيكتو غير مخصص للاستخدام مع النساء.</p><p dir="RTL">قبل استخدام بلوفيكتو، أخبري طبيب الطب النووي المتابع لكِ بما إذا كنتِ نشطة جنسيًا لأن جميع الأدوية المُشعة، بما في ذلك بلوفيكتو، من المحتمل أن تسبب ضررًا للأجنة.</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">قد يسبب بلوفيكتو العقم. يُرجى الاستفسار من طبيب الطب النووي المتابع لك عن مدى تأثير بلوفيكتو عليك في هذا السياق، خاصةً إذا كنت تخطط للإنجاب في المستقبل. فقد ترغب في طلب المشورة بشأن حفظ الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL"><u>وسائل منع الحمل لدى الذكور</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك تجنب النشاط الجنسي لمدة 7 أيام بعد تلقي بلوفيكتو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك عدم الإنجاب كما يجب عليك استخدام واقي ذكري أثناء الجماع طوال فترة العلاج باستخدام عقار بلوفيكتو ولمدة 14 أسبوعًا بعد تلقي جرعتك الأخيرة منه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيب الطب النووي المتابع لك على الفور بما إذا أنجبت في أي وقت خلال هذه الفترة الزمنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. قيادة السيارة واستعمال الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر بلوفيكتو على قدرتك في قيادة السيارة أو استعمال الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. معلومات مهمة حول بعض مكونات بلوفيكتو</strong></p><p dir="RTL"><strong>يحتوي بلوفيكتو على الصوديوم</strong></p><p>يحتوي هذا الدواء على 88.75 ملغ من الصوديوم (المكون الرئيسي لملح الطهي/الطعام) في كل قنينة. ويعادل ذلك 4.4% من الحد الأقصى المُوصى به للحصة الغذائية اليومية من الصوديوم لشخص بالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هناك قوانين صارمة بشأن استخدام المنتجات الصيدلانية المشعة والتعامل معها والتخلص منها. سيُستخدم بلوفيكتو فقط في المناطق الخاصة الخاضعة للمراقبة. سيتم التعامل مع منتج الدواء المشع هذا، وإعطاؤه لك فقط من قِبل أشخاص مدربين ومؤهلين لاستخدامه بأمان. سيتخذ هؤلاء الأشخاص احتياطات خاصة للاستخدام الآمن لمنتج الدواء المشع هذا، وسيطلعونك على ما ينفذونه من إجراءات في هذا الصدد.</p><p dir="RTL"><strong>كمية بلوفيكتو المُعطاة</strong></p><p dir="RTL">تبلغ جرعة نظام العلاج المُوصى بها من بلوفيكتو 400 7 ميغا بيكريل (ميغا بيكريل هي الوحدة المستخدمة للتعبير عن النشاط الإشعاعي)، والتي تُعطى كل 6 أسابيع تقريبًا بعدد يصل إلى 6 جرعات إجمالاً.</p><p dir="RTL"><strong>إعطاء بلوفيكتو وتنفيذ الإجراء</strong></p><p dir="RTL">يُعطى بلوفيكتو مباشرةً في الوريد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مدة الإجراء</strong></p><p dir="RTL">سيخبرك طبيب الطب النووي المتابع لك بالمدة المعتادة للإجراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة حول المدة التي ستستخدم فيها بلوفيكتو، فتحدث إلى طبيب الطب النووي المتابع لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مراقبة العلاج</strong></p><p dir="RTL">سيُجري طبيب الطب النووي المتابع لك اختبارات دم قبل العلاج وخلاله لفحص حالتك والكشف عن أي آثار جانبية في أقرب وقت ممكن. استنادًا إلى النتائج، قد يقرر طبيب الطب النووي المتابع لك تأجيل علاجك بعقار بلوفيكتو أو تغييره أو إيقافه إذا لزم الأمر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مواعيد استخدام بلوفيكتو</strong></p><p dir="RTL">استخدم بلوفيكتو:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد ساعتين على الأقل من تناول أي طعام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم انتظر ساعة واحدة على الأقل قبل تناول أي طعام مرة أخرى.</p><p dir="RTL">سيساعدك تناول هذا الدواء في نفس الوقت كل يوم على تذكر موعد تناوله.</p><p dir="RTL"><strong>يعد إعطاء بلوفيكتو، يجب عليك:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرب الكثير من الماء لمدة يومين حتى تحافظ على ترطيب جسمك والتبول قدر الإمكان لإخراج منتج الدواء المشع من جسمك</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأن هذا الدواء مشع، فسيتعين عليك اتباع التعليمات الموضحة أدناه للحد من تعرض الآخرين للإشعاع ما لم يطلب منك طبيب الطب النووي المتابع لك خلاف ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مخالطة الآخرين في منزلك و/أو الأطفال و/أو النساء الحوامل</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على الحد من المخالطة عن قُرب (أقل من متر) مع:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآخرين في منزلك لمدة يومين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال والنساء الحوامل لمدة 7 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص على النوم في غرفة نوم منفصلة عن:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآخرين في منزلك لمدة 3 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال لمدة 7 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النساء الحوامل لمدة 15 يومًا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب ممارسة النشاط الجنسي لمدة 7 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك عدم الإنجاب كما يجب عليك استخدام واقي ذكري أثناء الجماع طوال فترة العلاج باستخدام عقار بلوفيكتو ولمدة 14 أسبوعًا بعد تلقي جرعتك الأخيرة منه</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>استخدام المراحيض</u></p><p dir="RTL">يجب عليك اتخاذ احتياطات خاصة لتجنب التلوث لمدة يومين بعد إعطاء بلوفيكتو:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تجلس دائمًا عند استخدام المرحاض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الضروري أن تستخدم ورق المرحاض في كل مرة تستعمل فيها المرحاض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك دائمًا جيدًا بعد استخدام المرحاض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اشطف جميع المناديل و/أو ورق المرحاض في المرحاض مباشرةً بعد الاستخدام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اشطف أي أنسجة أو أي عناصر أخرى تحتوي على نفايات جسدية، مثل الدم والبول والبراز، في المرحاض. يجب وضع الأشياء التي لا يمكن شطفها في المرحاض، مثل الضمادات، في أكياس بلاستيكية منفصلة مصممة للتخلص من النفايات (وفقًا لـ &quot;توصيات التخلص من النفايات&quot; أدناه).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تفريغ أي معدات طبية خاصة قد تكون ملوثة بسوائل جسمك (مثل أكياس القسطرة، وأكياس فغر القولون، وأوعية التّبوّل بالفراش، وفوهات الماء) على الفور في المرحاض ثم تنظيفها.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الاستحمام والغسيل</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استحم كل يوم لمدة 7 أيام على الأقل بعد إعطاء بلوفيكتو.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل ملابسك الداخلية والبيجامات والملاءات وأي ملابس تحتوي على العرق أو الدم أو البول بشكل منفصل عن غسيل الآخرين في منزلك، باستخدام دورة غسيل قياسية. لستَ بحاجة إلى استخدام مبيض أو شطف إضافي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مقدمو الرعاية</u></p><p dir="RTL">لمدة يومين إلى 3 أيام بعد إعطاء بلوفيكتو:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُفضل أن يتلقى الأشخاص ملازمو الفراش أو الذين يعانون من ضعف الحركة المساعدة من مقدم رعاية. يوصى بأن يرتدي مقدم الرعاية قفازات صالحة للاستعمال مرة واحدة فقط عند تقديم المساعدة في الحمام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على مقدمي الرعاية الذين ينظفون القيء أو الدم أو البول أو البراز ارتداء قفازات بلاستيكية، والتي يجب التخلص منها في كيس بلاستيكي منفصل مصمم للتخلص من النفايات (انظر &quot;توصيات التخلص من النفايات&quot; أدناه).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>توصيات التخلص من النفايات</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخلص من جميع العناصر المطلوب التخلص منها في كيس بلاستيكي منفصل مصمم للتخلص من النفايات ومُستخدم فقط لهذا الغرض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بأكياس التخلص من النفايات البلاستيكية بشكل منفصل عن النفايات المنزلية الأخرى، وبعيدًا عن متناول الأطفال والحيوانات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك أحد طاقم عمل المستشفى بكيفية التخلص من أكياس التخلص من النفايات هذه وتوقيت ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>دخول المستشفى والرعاية الطارئة</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا احتجت لأي سبب من الأسباب إلى مساعدة طبية طارئة أو دخلت المستشفى بشكل غير متوقع خلال الأيام السبعة الأولى بعد إعطاء بلوفيكتو، فيجب عليك إبلاغ اختصاصيي الرعاية الصحية باسم علاجك الإشعاعي وتاريخ تلقيه والجرعة التي تلقيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>احتياطات أخرى</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيب الطب النووي بما إذا كنت بحاجة إلى اتخاذ أي احتياطات خاصة أخرى بعد تلقي هذا الدواء. اتصل بطبيب الطب النووي المتابع لك إذا كانت لديك أي أسئلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ. إذا أُعطيت جرعة زائدة من بلوفيكتو</strong></p><p dir="RTL">من غير المحتمل أن تتلقى جرعة زائدة لأنك لن تتلق بلوفيكتو إلا بجرعات خاضعة للمراقبة الدقيقة من قِبل طبيب الطب النووي المشرف على الإجراء. ومع ذلك، في حالة تلقي جرعة زائدة، ستتلقى العلاج المناسب.</p><p dir="RTL"><strong>ب. إذا نسيتَ تلقي بلوفيكتو</strong></p><p dir="RTL">إذا فاتك موعد تلقي بلوفيكتو، فاتصل بطبيب الطب النووي المتابع لك في أقرب وقت ممكن لتحديد موعد جديد.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام بلوفيكتو، فيُرجى طرحها على طبيب الطب النووي الذي يشرف على الإجراء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، بالرغم من أن هذه الآثار لا تصيب كل من يتلقاه.</p><p dir="RTL"><strong>قد تكون بعض الآثار الجانبية خطيرة</strong></p><p dir="RTL">إذا عانيت من أي من الآثار الجانبية الخطيرة التالية، <strong>فأخبر طبيب الطب النووي المتابع لك فورًا.</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب أو ضعف أو شحوب الجلد أو ضيق في التنفس (علامات محتملة على انخفاض مستويات خلايا الدم الحمراء [<em>فقر</em><em>&nbsp;</em><em>الدم</em>])</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزف أو التكدم بسهولة تفوق المعتاد أو النزف لفترة أطول من المعتاد (علامات محتملة على انخفاض مستويات الصفائح الدموية [<em>قلة الصفيحات</em>])</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى متكررة مصحوبة بعلامات مثل الحمى أو التهاب الحلق أو قرح الفم (علامات محتملة على انخفاض مستويات خلايا الدم البيضاء [<em>قلة الكريات البيض، قلة اللمفاويات</em>])</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: </strong>قد تصيب شخصًا واحدًا على الأكثر من بين كل 10 أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التبول بوتيرة أقل أو بكميات أقل بكثير من المعتاد (علامة محتملة على وجود مشكلات في الكلى [<em>قصور كلوي حاد]</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب أو ضعف أو شحوب الجلد أو ضيق في التنفس أو النزف أو التكدم بسهولة تفوق المعتاد أو النزف لفترة أطول من المعتاد أو حالات عدوى متكررة مصحوبة بعلامات مثل الحمى أو القشعريرة أو التهاب الحلق أو قرح الفم (علامات محتملة على انخفاض مستويات خلايا الدم [<em>قلة الكريات الشاملة</em>])</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى</strong></p><p dir="RTL">تشمل الآثار الجانبية الأخرى ما هو مذكور أذناه. إذا أصبحت هذه الآثار الجانبية خطيرة، فيُرجى إخبار طبيب الطب النووي المتابع لك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: </strong>قد تصيب أكثر من شخص واحد من كل 10 أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب (<em>إرهاق</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في التبرز (<em>إمساك أو إسهال</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول متكرر مصحوب بألم أو إحساس بالحرقان (<em>عدوى بالمسالك البولية</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL"><strong>شائعة: </strong>قد تصيب شخصًا واحدًا على الأكثر من بين كل 10 أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو الكاحلين أو القدمين (<em>وذمة طرفية</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حاسة التذوق (<em>خلل الذوق</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (<em>سخونة</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العينين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة، مصحوبة بإحساس بالدوران (<em>دوار</em>)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرّضت لأي آثار جانبية، فتحدّث إلى طبيبك أو الصيدلي. يشمل هذا أيّ آثار جانبية محتملة غير مذكورة في هذه النشرة. بإبلاغك عن الآثار الجانبية، فإنّك تساعد في توفير المزيد من المعلومات حول مدى سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لن تضطر إلى تخزين هذا الدواء. يُخزن هذا الدواء تحت مسؤولية الاختصاصي في الأماكن المناسبة. ستُخزن الأدوية المشعة وفقًا للوائح الوطنية الخاصة بالمواد المشعة.</p><p dir="RTL">إن المعلومات التالية مخصصة للاختصاصي فقط:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تجمّده.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في العبوة الأصلية لحمايته من الإشعاع المؤين (التدريع بالرصاص).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام بلوفيكتو بعد تاريخ ووقت انتهاء الصلاحية الموضحين على حاوية التدريع بالرصاص وملصقات القنينة بعد كلمة EXP.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخلص من أي منتج دوائي أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. محتويات بلوفيكتو</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي اللوتيشيوم (<sup>177</sup>Lu) فيبيفوتايد تتراكسيتان. يحتوي كل مل من المحلول على 1000 ميغا بيكريل من اللوتيشيوم (<sup>177</sup>Lu) فيبيفوتايد تتراكسيتان في تاريخ ووقت المعايرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: حمض الأسيتيك، أسيتات الصوديوم، حمض الجنتيسيك، أسكوربات الصوديوم، حمض البنتيتيك، ماء للحقن (انظر &quot;يحتوي بلوفيكتو على الصوديوم&quot; في القسم 2).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بلوفيكتو هو محلول شفاف عديم اللون مائل إلى الأصفر قليلاً يتم توفيره في قنينة زجاجية شفافة عديمة اللون من النوع الأول، مغلقة بسدادة مطاطية مصنوعة من البروموبوتيل ومانع تسرب مصنوع من الألومنيوم.</p><p dir="RTL">تحتوي كل قنينة على كمية من المحلول يمكن أن تتراوح من 7.5 مل إلى 12.5 مل بما يماثل نشاط إشعاعي يبلغ 7&nbsp;400&nbsp;ميغا بيكريل &plusmn;10% في تاريخ ووقت إعطاء بلوفيكتو.</p><p dir="RTL">القنينة مغلقة بحاوية رصاصية للحماية الواقية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل ترخيص التسويق لهذا المنتج هو شركة Novartis Europharm Limited، أيرلندا</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر موافقة/مراجعة على هذه النشرة في 12/2022 من قِبل وكالة الأدوية الأوروبية (EMA)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pluvicto 1 000 MBq/mL solution for injection/infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One mL of solution contains 1 000 MBq of lutetium (177Lu) vipivotide tetraxetan at the date and time of calibration.

The total amount of radioactivity per single dose vial is 7 400 MBq ± 10% at the date and time of administration. Given the fixed volumetric activity of 1 000 MBq/mL at the date and time of calibration, the volume of the solution in the vial can range from 7.5 mL to 12.5 mL in order to provide the required amount of radioactivity at the date and time of administration.

Physical characteristics

Lutetium 177 decays to a stable hafnium 177 with a physical half life of 6.647 days by emitting beta minus radiation with a maximum energy of 0.498 MeV (79%) and photon radiation (γ) of 0.208 MeV (11%) and 0.113 MeV (6.4%).

Excipient with known effect

Each mL of solution contains up to 0.312 mmol (7.1 mg) of sodium. Each vial contains up to 88.75 mg of sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion.

Clear, colourless to slightly yellow solution, pH: 4.5 to 7.0.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p>&nbsp;</p><p>Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate‑specific membrane antigen (PSMA)‑positive metastatic castration‑resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane‑based chemotherapy (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Important safety instructions</u></p><p>&nbsp;</p><p>Pluvicto should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings (see section&nbsp;6.6) and after evaluation of the patient by a qualified physician.</p><p>&nbsp;</p><p>Radiopharmaceuticals, including Pluvicto, should be used by or under the control of healthcare professionals who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorised to license the use of radiopharmaceuticals.</p><p>&nbsp;</p><p><u>Patient identification</u></p><p>&nbsp;</p><p>Patients should be identified for treatment by PSMA imaging.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended treatment regimen of Pluvicto is 7&nbsp;400&nbsp;MBq intravenously every 6&nbsp;weeks (&plusmn;1&nbsp;week) for up to a total of 6&nbsp;doses, unless there is disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Medical castration with a gonadotropin‑releasing hormone (GnRH) analogue should be continued during treatment in patients not surgically castrated.</p><p>&nbsp;</p><p><em><u>Treatment monitoring</u></em></p><p>Laboratory tests should be performed before and during treatment with Pluvicto. Dosing may need to be modified based on the test results (see Table&nbsp;1).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haematology (haemoglobin, white blood cell count, absolute neutrophil count, platelet count)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney function (serum creatinine, calculated creatinine clearance [CLcr])</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver function (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, blood serum albumin, total blood bilirubin)</p><p>&nbsp;</p><p><em><u>Dose modifications for adverse reactions</u></em></p><p>Recommended dose modifications of Pluvicto for adverse reactions are provided in Table&nbsp;1. Management of severe or intolerable adverse reactions may require temporary dose interruption (extending the dosing interval by 4&nbsp;weeks from 6&nbsp;weeks up to 10&nbsp;weeks), dose reduction or permanent discontinuation of treatment with Pluvicto. If a treatment delay due to an adverse reaction persists for &gt;4&nbsp;weeks, treatment with Pluvicto must be discontinued. The dose of Pluvicto may be reduced by 20% once; the dose should not be re‑escalated. If a patient has further adverse reactions that would require an additional dose reduction, treatment with Pluvicto must be discontinued.</p><p>&nbsp;</p><p><strong>Table</strong><strong>&nbsp;1 Recommended dose modifications </strong><strong>of Pluvicto for adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Adverse reaction</p></td><td><p>Severity<sup>a</sup></p></td><td><p>Dose modification</p></td></tr><tr><td><p>Dry mouth</p></td><td><p>Grade&nbsp;3</p></td><td><p>Reduce<sup> </sup>Pluvicto dose by 20%.</p></td></tr><tr><td><p>Gastrointestinal toxicity</p></td><td><p>Grade&nbsp;&ge;3 (not amenable to medical intervention)</p></td><td><p>Withhold Pluvicto until improvement to grade&nbsp;2 or baseline.</p><p>Reduce<sup> </sup>Pluvicto dose by 20%.</p></td></tr><tr><td rowspan="2"><p>Anaemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia</p></td><td><p>Grade&nbsp;2</p></td><td><p>Withhold Pluvicto until improvement to grade&nbsp;1 or baseline.</p><p>Manage as deemed appropriate. The use of growth factors is permitted but should be discontinued once improved to grade&nbsp;1 or baseline. Checking haematinic levels (iron, B12 and folate) and providing supplementation is advocated. Transfusions may be given as clinically indicated.</p></td></tr><tr><td><p>Grade&nbsp;&ge;3</p></td><td><p>Withhold Pluvicto until improvement to grade&nbsp;1 or baseline.</p><p>Reduce Pluvicto dose by 20%.</p></td></tr><tr><td rowspan="3"><p>Renal toxicity</p></td><td><p>Defined as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirmed serum creatinine increase (grade&nbsp;&ge;2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirmed CLcr &lt;50&nbsp;mL/min; calculate using Cockcroft‑Gault with actual body weight</p></td><td><p>Withhold Pluvicto until improvement.</p></td></tr><tr><td><p>Defined as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirmed &ge;40% increase from baseline serum creatinine</p><p><u>and</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirmed &gt;40% decrease from baseline CLcr; calculate using Cockcroft‑Gault with actual body weight</p></td><td><p>Withhold Pluvicto until improvement or return to baseline.</p><p>Reduce Pluvicto dose by 20%.</p></td></tr><tr><td><p>Recurrent renal toxicity (grade&nbsp;&ge;3)</p></td><td><p>Permanently discontinue Pluvicto.</p></td></tr><tr><td><p>Spinal cord compression</p></td><td><p>Any</p></td><td><p>Withhold Pluvicto until the compression has been adequately treated and any neurological sequela have stabilised and ECOG performance status has stabilised.</p></td></tr><tr><td><p>Fracture in weight‑bearing bones</p></td><td><p>Any</p></td><td><p>Withhold Pluvicto until the fracture has been adequately stabilised/treated and ECOG performance status has stabilised.</p></td></tr><tr><td><p>Fatigue</p></td><td><p>Grade&nbsp;&ge;3</p></td><td><p>Withhold Pluvicto until improvement to Grade&nbsp;2 or baseline.</p></td></tr><tr><td><p>Electrolyte or metabolic abnormalities</p></td><td><p>Grade&nbsp;&ge;2</p></td><td><p>Withhold Pluvicto until improvement to Grade&nbsp;1 or baseline.</p></td></tr><tr><td><p>Non‑haematological toxicity (clinically significant, not otherwise stated)</p></td><td><p>Grade&nbsp;&ge;2</p></td><td><p>Withhold Pluvicto until improvement to Grade&nbsp;1 or baseline.</p></td></tr><tr><td><p>AST or ALT elevation</p></td><td><p>AST or ALT &gt;5&nbsp;times ULN in the absence of liver metastases</p></td><td><p>Permanently discontinue Pluvicto.</p></td></tr><tr><td colspan="3"><p>Abbreviations: CLcr, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal.</p><p>Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE).</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; The same thresholds are also applicable to baseline values at the time of treatment initiation with Pluvicto.</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly</em></p><p>No dose adjustment is recommended in patients aged 65&nbsp;years or older.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is recommended for patients with mild to moderate renal impairment with baseline CLcr &ge;50&nbsp;mL/min by Cockcroft‑Gault. Treatment with Pluvicto is not recommended in patients with moderate to severe renal impairment with baseline CLcr &lt;50&nbsp;mL/min or end‑stage renal disease as the pharmacokinetic profile and safety of Pluvicto have not been studied in these patients (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is recommended for patients with hepatic impairment. Pluvicto has not been studied in patients with moderate or severe hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of Pluvicto in the paediatric population in the indication of treatment of PSMA‑expressing prostate cancer.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Pluvicto is a ready‑to‑use solution for injection/infusion for single use only.</p><p>&nbsp;</p><p><em><u>Administration instructions</u></em></p><p>The recommended dose of Pluvicto may be administered intravenously as an injection using a disposable syringe fitted with a syringe shield (with or without a syringe pump), as an infusion using the gravity method (with or without an infusion pump), or as an infusion using the vial (with a peristaltic infusion pump).</p><p>&nbsp;</p><p>A reduced dose of Pluvicto should be administered using the syringe method (with or without a syringe pump) or the vial method (with a peristaltic infusion pump). Using the gravity method to administer a reduced dose of Pluvicto is not recommended since it may result in delivery of the incorrect volume of Pluvicto if the dose is not adjusted prior to administration.</p><p>&nbsp;</p><p>Prior to administration, flush the intravenous catheter used exclusively for Pluvicto administration with &ge;10&nbsp;mL of sterile sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection to ensure patency and to minimise the risk of extravasation. Cases of extravasation should be managed as per institutional guidelines. Patients should be advised to remain well hydrated and to urinate frequently before and after administration of Pluvicto (see section&nbsp;4.4).</p><p>&nbsp;</p><p>For instructions on the method of preparation and intravenous methods of administration, see section&nbsp;12.</p><p>&nbsp;</p><p>For patient preparation, see section&nbsp;4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Individual benefit/risk justification</u></p><p>&nbsp;</p><p>For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required therapeutic effect.</p><p><u>&nbsp;</u></p><p><u>Risk from radiation exposure</u></p><p>&nbsp;</p><p>Pluvicto contributes to a patient&rsquo;s overall long‑term cumulative radiation exposure. Long‑term cumulative radiation exposure is associated with an increased risk for cancer.</p><p>&nbsp;</p><p>Radiation exposure to patients, medical personnel, and household contacts should be minimised during and after treatment with Pluvicto consistent with institutional good radiation safety practices, patient management procedures, and instructions to the patient for follow‑up radiation protection at home.</p><p>&nbsp;</p><p><em><u>Patient preparation</u></em></p><p>Patients should be encouraged to increase oral fluids and urged to void as often as possible to reduce bladder radiation, especially after high activities, e.g. for radionuclide therapy.</p><p>&nbsp;</p><p><em><u>After the procedure</u></em></p><p>Before the patient is released, the nuclear medicine physician or healthcare professional should explain the necessary radioprotection precautions that the patient should follow to minimise radiation exposure to others.</p><p>&nbsp;</p><p>After each administration of Pluvicto, the following general recommendations for patients can be considered along with national, local and institutional procedures and regulations.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Limit close contact (less than 1&nbsp;metre) with others in their household for 2&nbsp;days or with children and pregnant women for 7&nbsp;days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refrain from sexual activity for 7&nbsp;days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep in a separate bedroom from others in their household for 3&nbsp;days, from children for 7&nbsp;days, or from pregnant women for 15&nbsp;days.</p><p>&nbsp;</p><p><u>Myelosuppression</u></p><p>&nbsp;</p><p>In the VISION study, myelosuppression, including fatal cases, occurred more frequently in patients who received Pluvicto plus best standard of care (BSoC) compared to patients who received BSoC alone (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Haematology laboratory tests, including haemoglobin, white blood cell count, absolute neutrophil count and platelet count, should be performed before and during treatment with Pluvicto. Pluvicto should be withheld, dose reduced or permanently discontinued and patients should be clinically managed as deemed appropriate based on the severity of myelosuppression (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Renal toxicity</u></p><p>&nbsp;</p><p>In the VISION study, renal toxicity occurred more frequently in patients who received Pluvicto plus BSoC compared to patients who received BSoC alone (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Before and after administration of Pluvicto, patients should be encouraged to increase oral fluids and urged to void as often as possible, especially after high activities, e.g. for radionuclide therapy. Kidney function laboratory tests, including serum creatinine and calculated CLcr, should be performed before and during treatment with Pluvicto. Pluvicto should be withheld, dose reduced or permanently discontinued based on the severity of renal toxicity (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Renal/Hepatic impairment</u></p><p>&nbsp;</p><p>Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible.</p><p>&nbsp;</p><p>Exposure (AUC) of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan is expected to increase with the degree of renal impairment (see section&nbsp;5.2). Patients with mild or moderate renal impairment may be at greater risk of toxicity. Renal function and adverse reactions should be frequently monitored in patients with mild to moderate renal impairment (see section&nbsp;4.2). Treatment with Pluvicto is not recommended in patients with moderate to severe renal impairment with baseline CLcr &lt;50&nbsp;mL/min or end‑stage renal disease.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Radiations of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan may potentially have toxic effects on male gonads and spermatogenesis. The recommended cumulative dose of 44&nbsp;400&nbsp;MBq of Pluvicto results in a radiation absorbed dose to the testes within the range where Pluvicto may cause infertility. Genetic consultation is recommended if the patient wishes to have children after treatment. Cryopreservation of sperm can be discussed as an option for male patients before treatment (see section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Contraception in males</u></p><p>&nbsp;</p><p>Male patients are advised not to father a child and to use a condom for intercourse during treatment with Pluvicto and for 14&nbsp;weeks after the last dose (see section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Specific warnings</u></p><p>&nbsp;</p><p><em><u>Sodium content</u></em></p><p>This medicinal product contains up to 3.9&nbsp;mmol (88.75&nbsp;mg) sodium per vial, equivalent to 4.4% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p><p>&nbsp;</p><p>Precautions with respect to environmental hazard see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinical drug interaction studies were performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraception in males</u></p><p>&nbsp;</p><p>Because of potential effects on spermatogenesis associated with radiations of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan, male patients are advised not to father a child and to use a condom for intercourse during treatment with Pluvicto and for 14&nbsp;weeks after the last dose (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Pluvicto is not indicated for use in females. No animal studies using lutetium (<sup>177</sup>Lu) vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo‑foetal development. However, all radiopharmaceuticals, including Pluvicto, have the potential to cause foetal harm when administered to a pregnant woman.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>Pluvicto is not indicated for use in females. There are no data on the presence of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan in human milk or its effects on the breast‑fed newborn/infant or on milk production.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No studies were conducted to determine the effects of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan on fertility. Radiations of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan may potentially have toxic effects on male gonads and spermatogenesis. The recommended cumulative dose of 44&nbsp;400&nbsp;MBq of Pluvicto results in a radiation absorbed dose to the testes within the range where Pluvicto may cause infertility. Genetic consultation is recommended if the patient wishes to have children after treatment. Cryopreservation of sperm can be discussed as an option for male patients before treatment (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pluvicto may have a minor influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>Unless otherwise stated, the frequency of listed adverse reactions is based on data from the VISION study in which 529&nbsp;patients received at least one dose of 7&nbsp;400&nbsp;MBq (median number of doses was five).</p><p>&nbsp;</p><p>The most common adverse reactions include: fatigue (43.1%), dry mouth (39.3%), nausea (35.3%), anaemia (31.8%), decreased appetite (21.2%) and constipation (20.2%). The most common grade&nbsp;3 to 4 adverse reactions include: anaemia (12.9%), thrombocytopenia (7.9%), lymphopenia (7.8%) and fatigue (5.9%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions (Table&nbsp;2) are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse reaction is based on the following convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1&nbsp;000 to &lt;1/100); rare (&ge;1/10&nbsp;000 to &lt;1/1&nbsp;000); very rare (&lt;1/10&nbsp;000).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions occurring at a higher incidence in patients who received Pluvicto plus BSoC compared to BSoC alone in VISION<sup>a</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:92%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td><td style="vertical-align:top"><p><strong>All grades<br />n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grades<br />3 to 4<sup>b</sup><br />n (%)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>168 (31.8)</p></td><td style="vertical-align:top"><p>68 (12.9)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>91 (17.2)</p></td><td style="vertical-align:top"><p>42 (7.9)</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia<sup>c</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>83 (15.7)</p></td><td style="vertical-align:top"><p>22 (4.2)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>75 (14.2)</p></td><td style="vertical-align:top"><p>41 (7.8)</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia<sup>d</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9 (1.7)</p></td><td style="vertical-align:top"><p>7 (1.3)<sup>b</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>44 (8.3)</p></td><td style="vertical-align:top"><p>5 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>37 (7.0)</p></td><td style="vertical-align:top"><p>4 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia<sup>e</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>37 (7.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dry eye</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (3.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>11 (2.1)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth<sup>f</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>208 (39.3)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>187 (35.3)</p></td><td style="vertical-align:top"><p>7 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>107 (20.2)</p></td><td style="vertical-align:top"><p>6 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting<sup>g</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>101 (19.1)</p></td><td style="vertical-align:top"><p>5 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>100 (18.9)</p></td><td style="vertical-align:top"><p>4 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>h</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>59 (11.2)</p></td><td style="vertical-align:top"><p>6 (1.1)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection<sup>i</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>61 (11.5)</p></td><td style="vertical-align:top"><p>20 (3.8)</p></td></tr><tr><td style="vertical-align:top"><p>Acute kidney injury<sup>j</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>45 (8.5)</p></td><td style="vertical-align:top"><p>17 (3.2)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>228 (43.1)</p></td><td style="vertical-align:top"><p>31 (5.9)</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>112 (21.2)</p></td><td style="vertical-align:top"><p>10 (1.9)</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>57 (10.8)</p></td><td style="vertical-align:top"><p>2 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral<sup>k</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>52 (9.8)</p></td><td style="vertical-align:top"><p>2 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>36 (6.8)</p></td><td style="vertical-align:top"><p>2 (0.4)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Abbreviation: BSoC, best standard of care.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Only includes grades&nbsp;3 to 4 adverse reactions, with the exception of pancytopenia. Grade&nbsp;5 (fatal) pancytopenia was reported in 2&nbsp;patients who received Pluvicto plus BSoC.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia includes leukopenia and neutropenia.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; Pancytopenia includes pancytopenia and bicytopenia.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Dysgeusia includes dysgeusia and taste disorder.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth includes dry mouth, aptyalism and dry throat.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp;&nbsp; Vomiting includes vomiting and retching.</p><p><sup>h</sup>&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, abdominal tenderness and gastrointestinal pain.</p><p><sup>i</sup>&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection includes urinary tract infection, cystitis and cystitis bacterial.</p><p><sup>j</sup>&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney injury includes blood creatinine increased, acute kidney injury, renal failure and blood urea increased.</p><p><sup>k</sup>&nbsp;&nbsp;&nbsp;&nbsp; Oedema peripheral includes oedema peripheral, fluid retention and fluid overload.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Myelosuppression</u></em></p><p>In the VISION study, myelosuppression occurred more frequently in patients who received Pluvicto plus BSoC compared to patients who received BSoC alone (all grades/grade&nbsp;&ge;3): anaemia (31.8%/12.9%) versus (13.2%/4.9%); thrombocytopenia (17.2%/7.9%) versus (4.4%/1.0%); leukopenia (12.5%/2.5%) versus (2.0%/0.5%); lymphopenia (14.2%/7.8%) versus (3.9%/0.5%); neutropenia (8.5%/3.4%) versus (1.5%/0.5%); pancytopenia (1.5%/1.1%) versus (0%/0%) including two fatal events of pancytopenia in patients who received Pluvicto plus BSoC; and bicytopenia (0.2%/0.2%) versus (0%/0%).</p><p>&nbsp;</p><p>Myelosuppression adverse reactions that led to permanent discontinuation in &ge;0.5% of patients who received Pluvicto plus BSoC included: anaemia (2.8%), thrombocytopenia (2.8%), leukopenia (1.3%), neutropenia (0.8%) and pancytopenia (0.6%). Myelosuppression adverse reactions that led to dose interruptions/dose reductions in &ge;0.5% of patients who received Pluvicto plus BSoC included: anaemia (5.1%/1.3%), thrombocytopenia (3.6%/1.9%), leukopenia (1.5%/0.6%) and neutropenia (0.8%/0.6%).</p><p>&nbsp;</p><p><em><u>Renal toxicity</u></em></p><p>In the VISION study, renal toxicity occurred more frequently in patients who received Pluvicto plus BSoC compared to patients who received BSoC alone (all grades/grades&nbsp;3 to 4): blood creatinine increased (5.3%/0.2%) versus (2.4%/0.5%); acute kidney injury (3.6%/3.0%) versus (3.9%/2.4%); renal failure (0.2%/0%) versus (0%/0%); and blood urea increased (0.2%/0%) versus (0%/0%).</p><p>&nbsp;</p><p>Renal adverse reactions that led to permanent discontinuation in &ge;0.2% of patients who received Pluvicto plus BSoC included: blood creatinine increased (0.2%). Renal adverse reactions that led to dose interruptions/dose reductions in &ge;0.2% of patients who received Pluvicto plus BSoC included: blood creatinine increased (0.2%/0.4%) and acute kidney injury (0.2%/0%).</p><p>&nbsp;</p><p><em><u>Second primary malignancies</u></em></p><p>Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations. In all cases it is necessary to ensure that the risks of the radiation are less than from the disease itself. As Pluvicto contributes to a patient&rsquo;s overall long‑term radiation exposure, which is associated with an increased risk for cancer (see section&nbsp;4.4), a potential risk of second primary malignancies cannot be ruled out for radiopharmaceuticals such as Pluvicto. At the time of the VISION primary analysis (cut‑off date 27‑Jan‑2021), cases of squamous cell carcinoma (4&nbsp;patients; 0.8%) and basal cell carcinoma, malignant melanoma and squamous cell carcinoma of the skin (1&nbsp;patient each; 0.2% each) were reported in patients who received Pluvicto plus BSoC.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o Fax: +966-11-205-7662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of administration of a radiation overdose with Pluvicto, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by frequent micturition or by forced diuresis and frequent bladder voiding. It might be helpful to estimate the effective dose that was applied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: Therapeutic radiopharmaceuticals, Other therapeutic radiopharmaceuticals, ATC code: V10XX05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The active moiety of Pluvicto is the radionuclide lutetium‑177 which is linked to a small‑molecule ligand that targets and binds with high affinity to PSMA, a transmembrane protein that is highly expressed in prostate cancer, including mCRPC. Upon the binding of Pluvicto to PSMA‑expressing cancer cells, the beta‑minus emission from lutetium‑177 delivers therapeutic radiation to the targeted cell, as well as to surrounding cells, and induces DNA damage which can lead to cell death.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Unlabelled vipivotide tetraxetan does not have any pharmacodynamic activity.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>VISION</u></em></p><p>The efficacy of Pluvicto in patients with progressive, PSMA‑positive mCRPC was evaluated in VISION, a randomised, multicentre, open‑label phase&nbsp;III study. Eight hundred and thirty‑one (N=831) adult patients were randomised (2:1) to receive either Pluvicto 7&nbsp;400&nbsp;MBq every 6&nbsp;weeks for up to a total of 6&nbsp;doses plus best standard of care (BSoC) (N=551) or BSoC alone (N=280). Patients who received 4&nbsp;doses of Pluvicto were reassessed for evidence of response, signs of residual disease, and tolerability and could receive up to 2&nbsp;additional doses per physician&rsquo;s discretion.</p><p>&nbsp;</p><p>To maintain castration status, all patients continued to receive a GnRH analogue or had prior bilateral orchiectomy. Eligible patients were required to have progressive, PSMA‑positive mCRPC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, at least one metastatic lesion present on computed tomography (CT), magnetic resonance imaging (MRI) or bone scan imaging, and adequate renal, hepatic and haematological function.</p><p>&nbsp;</p><p>Eligible patients were also required to have received at least one AR pathway inhibitor, such as abiraterone acetate or enzalutamide, and 1 or 2 prior taxane‑based chemotherapy regimens (with a regimen defined as a minimum exposure of 2&nbsp;cycles of a taxane). Patients treated with only 1 prior taxane‑based chemotherapy regimen were eligible if the patient was unwilling or the physician deemed the patient unsuitable to receive a second regimen. Patients with unstable symptomatic central nervous system metastases or symptomatic or clinically/radiologically impending spinal cord compression were not eligible for the study. Patients underwent a gallium (<sup>68</sup>Ga) gozetotide positron emission tomography (PET) scan to evaluate PSMA expression in lesions defined by central read criteria. Eligible patients were required to have PSMA‑positive mCRPC defined as having at least one tumour lesion with gallium (<sup>68</sup>Ga) gozetotide uptake greater than in normal liver. Patients were excluded if any lesions exceeding size criteria in short axis (organs &ge;1&nbsp;cm, lymph nodes &ge;2.5&nbsp;cm, bones [soft‑tissue component] &ge;1&nbsp;cm) had uptake less than or equal to uptake in normal liver.</p><p>&nbsp;</p><p>BSoC administered at the physician&rsquo;s discretion included: supportive measures including pain management, hydration, blood transfusions, etc.; ketoconazole; radiation therapy (including seeded form or any external beam radiotherapy [including stereotactic body radiotherapy and palliative external beam]) to localised prostate cancer targets; bone‑targeted agents including zoledronic acid, denosumab and any bisphosphonates; androgen‑reducing agents including GnRH analogues, any corticosteroid, and 5‑alpha reductases; AR pathway inhibitors. BSoC excluded investigational agents, cytotoxic chemotherapy, immunotherapy, other systemic radioisotopes and hemi‑body radiotherapy treatment.</p><p>&nbsp;</p><p>Patients continued randomised treatment until evidence of tumour progression (based on investigator assessment per Prostate Cancer Working Group&nbsp;3 [PCWG3] criteria), unacceptable toxicity, use of prohibited treatment, non‑compliance or withdrawal, or lack of clinical benefit.</p><p>&nbsp;</p><p>The primary efficacy endpoints were overall survival (OS) and radiographic progression‑free survival (rPFS) as determined by blinded independent central review (BICR) per PCWG3 criteria. Among the secondary efficacy endpoints were overall response rate (ORR) as determined by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and time to first symptomatic skeletal event (SSE) defined as first new symptomatic pathological bone fracture, spinal cord compression, tumour‑related orthopaedic surgical intervention, requirement for radiation therapy to relieve bone pain, or death from any cause, whichever occurred first. Radiographic imaging for tumour assessment (CT with contrast/MRI imaging and bone scan) was done every 8&nbsp;weeks (&plusmn;4&nbsp;days) after the first dose for the first 24&nbsp;weeks (independent of dose delays), then every 12&nbsp;weeks (&plusmn;4&nbsp;days).</p><p>&nbsp;</p><p>Demographic and baseline disease characteristics were balanced between the treatment arms. The median age was 71&nbsp;years (range:&nbsp;40 to 94&nbsp;years); 86.8% White; 6.6% Black or African American; 2.4% Asian; 92.4% had ECOG PS0‑1; 7.6% had ECOG PS2. Randomisation was stratified by baseline lactate dehydrogenase (LDH &le;260&nbsp;IU/L vs. &gt;260&nbsp;IU/L), presence of liver metastases (yes vs. no), ECOG PS score (0 or 1 vs. 2), and inclusion of an AR pathway inhibitor as part of BSoC at the time of randomisation (yes vs. no). At randomisation, all patients (100.0%) had received at least one prior taxane‑based chemotherapy regimen and 41.2% of patients had received two; 97.1% of patients had received docetaxel and 38.0% of patients had received cabazitaxel. At randomisation, 51.3% of patients had received one prior AR pathway inhibitor, 41.0% of patients had received 2, and 7.7% of patients had received 3 or more. During the randomised treatment period, 52.6% of patients in the Pluvicto plus BSoC arm and 67.8% of patients in the BSoC alone arm received at least one AR pathway inhibitor.</p><p>&nbsp;</p><p>Efficacy results for VISION are presented in Table&nbsp;3 and Figures&nbsp;1 and 2. The final analyses of OS and rPFS were event‑driven and conducted after the occurrence of 530&nbsp;deaths and 347&nbsp;events, respectively.</p><p>&nbsp;</p><p><strong>Table&nbsp;3 Efficacy results in VISION</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy parameters</strong></p></td><td style="vertical-align:top"><p><strong>Pluvicto plus BsoC</strong></p></td><td style="vertical-align:top"><p><strong>BSoC</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Alternate primary efficacy endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival (OS)</strong><sup>a</sup></p></td><td style="vertical-align:top"><p>N=551</p></td><td style="vertical-align:top"><p>N=280</p></td></tr><tr><td style="vertical-align:top"><p>Deaths, n (%)</p></td><td style="vertical-align:top"><p>343 (62.3%)</p></td><td style="vertical-align:top"><p>187 (66.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>15.3 (14.2; 16.9)</p></td><td style="vertical-align:top"><p>11.3 (9.8; 13.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup> </sup>(95% CI)<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.62 (0.52; 0.74)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Radiographic progression‑free survival (rPFS)<sup>e,f</sup></strong></p></td><td style="vertical-align:top"><p>N=385</p></td><td style="vertical-align:top"><p>N=196</p></td></tr><tr><td style="vertical-align:top"><p>Events (progression or death), n (%)</p></td><td style="vertical-align:top"><p>254 (66.0%)</p></td><td style="vertical-align:top"><p>93 (47.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Radiographic progressions, n (%)</p></td><td style="vertical-align:top"><p>171 (44.4%)</p></td><td style="vertical-align:top"><p>59 (30.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Deaths, n (%)</p></td><td style="vertical-align:top"><p>83 (21.6%)</p></td><td style="vertical-align:top"><p>34 (17.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (99.2% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>8.7 (7.9; 10.8)</p></td><td style="vertical-align:top"><p>3.4 (2.4; 4.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (99.2% CI)<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.40 (0.29; 0.57)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Secondary efficacy endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to first symptomatic skeletal event (SSE)<sup>f</sup></strong></p></td><td style="vertical-align:top"><p>N=385</p></td><td style="vertical-align:top"><p>N=196</p></td></tr><tr><td style="vertical-align:top"><p>Events (SSE or death), n (%)</p></td><td style="vertical-align:top"><p>256 (66.5%)</p></td><td style="vertical-align:top"><p>137 (69.9%)</p></td></tr><tr><td style="vertical-align:top"><p>SSEs, n (%)</p></td><td style="vertical-align:top"><p>60 (15.6%)</p></td><td style="vertical-align:top"><p>34 (17.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Deaths, n (%)</p></td><td style="vertical-align:top"><p>196 (50.9%)</p></td><td style="vertical-align:top"><p>103 (52.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>11.5 (10.3; 13.2)</p></td><td style="vertical-align:top"><p>6.8 (5.2; 8.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.50 (0.40; 0.62)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value<sup>g</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Best overall response (BOR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Patients with evaluable disease at baseline</p></td><td style="vertical-align:top"><p>N=319</p></td><td style="vertical-align:top"><p>N=120</p></td></tr><tr><td style="vertical-align:top"><p>Complete response (CR), n (%)</p></td><td style="vertical-align:top"><p>18 (5.6%)</p></td><td style="vertical-align:top"><p>0 (0%)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response (PR), n (%)</p></td><td style="vertical-align:top"><p>77 (24.1%)</p></td><td style="vertical-align:top"><p>2 (1.7%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response rate (ORR)<sup>h,i</sup></strong></p></td><td style="vertical-align:top"><p>95 (29.8%)</p></td><td style="vertical-align:top"><p>2 (1.7%)</p></td></tr><tr><td style="vertical-align:top"><p>P‑value<sup>j</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)<sup>h</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>9.8 (9.1; 11.7)</p></td><td style="vertical-align:top"><p>10.6 (NE; NE)<sup>k</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>BSoC: Best standard of care; CI: Confidence interval; NE: Not evaluable; BICR: Blinded independent central review; PCWG3: Prostate Cancer Working Group&nbsp;3; RECIST: Response Evaluation Criteria in Solid Tumors.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Analysed on an intent‑to‑treat (ITT) basis in all randomised patients.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimate.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio based on the stratified Cox PH model. Hazard ratio &lt;1 favours Pluvicto plus BSoC.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; Stratified log‑rank test one‑sided p‑value.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; By BICR per PCWG3 criteria. The primary analysis of rPFS included censoring of patients who had &ge;2 consecutive missed tumour assessments immediately prior to progression or death. Results for rPFS with and without censoring for missed assessments were consistent.</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp; Analysed on an ITT basis in all patients randomised on or after 05-Mar-2019, when actions were implemented to mitigate early drop‑out from BSoC arm.</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp;&nbsp; Stratified log‑rank test two‑sided p‑value.</p><p><sup>h</sup>&nbsp;&nbsp;&nbsp;&nbsp; By BICR per RECIST v1.1.</p><p><sup>i</sup>&nbsp;&nbsp;&nbsp;&nbsp; ORR: CR+PR. Confirmed response for CR and PR.</p><p><sup>j</sup>&nbsp;&nbsp;&nbsp;&nbsp; Stratified Wald&rsquo;s Chi‑square test two‑sided p‑value.</p><p><sup>k</sup>&nbsp;&nbsp;&nbsp;&nbsp; Median DOR in the BSoC only arm was not reliable since only 1 of the 2&nbsp;patients who responded had RECIST v1.1 radiographic progression or death.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Kaplan‑Meier plot of OS in VISION</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
 margin-left:0;margin-top:68.45pt;width:17.05pt;height:143.55pt;z-index:251662336;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
    lang=DE-CH style='font-size:9.0pt;mso-bidi-font-size:8.0pt;mso-ansi-language:
    DE-CH'>Event-free probability (%)</span><span lang=EN-GB style='font-size:
    9.0pt;mso-bidi-font-size:8.0pt'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--><img width="27" height="195" alt="Text Box: Event-free probability (%)" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1032" type="#_x0000_t202" style='position:absolute;margin-left:177.4pt;
 margin-top:309.4pt;width:158.75pt;height:13.4pt;z-index:251661312;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time from randomisation (months)</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1031" type="#_x0000_t202"
 style='position:absolute;margin-left:58.35pt;margin-top:256.3pt;width:121.8pt;
 height:11.55pt;z-index:251660288;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA3Q37KCIDAADgBwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzcVdtOGzEQfa/Uf7D8DtmEJA0RCwIK
qBIFROADJl5v1sJrb22TC1/fY+8GKJWo1MtLN0oy9pw9njkztg+O1rVmS+m8sibn/d2MM2mELZRZ
5Pz+7nxnwpkPZArS1sicb6TnR4cfPxzQdOGoqZRgYDB+SjmvQmimvZ4XlazJ79pGGvhK62oKGLpF
r3C0AnOte4MsG/dqUoYfvlB9pkDs0anfoNJWPMjilMySPCi1mL6e6WLU4s+ZaWqWF66ZNTcuRi6u
ljeOqSLnUM5QDYl4r3N0MAx7b95avBCsS1dHvC1LtkYFxqPhpA+uTc6Hw/3s0yBr+eQ6MBEBo+F4
MgZAANEfjrNRBxDV9S8oRHX2PgnCbMOB8SpE38QAzfLnnPv726TvYnwnds0Gz+lHOAtrTCLQVGbf
XKJMnhl7WpFZyGPn7KqSVPiIaHWCoO06SbPtkj5yzVdfbQGB6THYxPeXtHtOm6aN8+FC2ppFI+dO
ipBWouWlD22AW0jUxFutinOldRq4xfxUO7YknfPz9HQ5/QDThq1yvj8ajBKzsfH91DK1CtIxreqc
T7L4tFJGgc5MkSCBlG5tBK1N6qyoTVw/rGepUFHyYhNn5viHbs4iFXQMtnm4xk+pLSIQWjWcVdY9
vZ2LOGwUeDhbYZPn3H97JCc5018MSgWqsDXc1phvDTICr+Y8cNaapwGjrEv2GLUrVSdlG1+MVPsw
CxstU5Ipi1jwmtxlWg7G7ZZDm1kjkt6NuAm+lbu/16qVVHnxn8jyLTKJCphvxIv3uAzv4DpvoDma
IOJgscZCib1xlg1HSFQvcHrqrtxbIFbpSpPq45CRRtvnXJqdixOcq0/oA8QdKWVZotfaJoMcFJRh
YdPIkgQ6/k7V0rMruWK3tibDWUPGejiyAT7jbA+nwBDfAawhvCqI6pxqpeMZgRNcVOS8TF2QFJb0
z8iRNBJNKh1e2V1EGpQ0qJMP6HNGgTnlH+KJCCkjOGVvihtydPtaoftZq1C//x9KJJ8TTiKg46Mg
zxv30ctZc4uGQLWSI+5sGPEk7r2525Kju4vjBfp6fPgdAAD//wMAUEsDBBQABgAIAAAAIQB2hWoV
VgYAAA8aAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWzsWUtvGzcQvhfof1jsvbHeio3I
ga1H3MROgkhJkSOlpXYZc5cLkrKjW5GceilQIC16aIDeeiiKBmiABr30xxhw0KY/okPuQ6RExQ+4
QFDEAozd2W+Gw5nZb0jujZtPY+odYS4ISzp+9VrF93AyYQFJwo7/cDT47LrvCYmSAFGW4I4/x8K/
uf3pJzfQ1oSSdMwQD0YRjrEHhhKxhTp+JGW6tbEhJiBG4hpLcQLPpozHSMItDzcCjo5hgJhu1CqV
1kaMSOJvg0WpDPUp/EukUIIJ5UNlBnsJimH0e9MpmWCNDQ6rCiHmoku5d4RoxwebATse4afS9ygS
Eh50/Ir+8ze2b2ygrVyJyjW6ht5A/+V6uUJwWNNj8nBcDtpoNButndK+BlC5iuu3+61+q7SnAWgy
gZlmvtg227VuI8caoOzSYbvX7tWrFt6wX1/xeaepfhZegzL7jRX8YNCFKFp4DcrwzRV8c3dzt2fb
16AM31rBtys7vUbbsq9BESXJ4Qq60mzVu8VsS8iU0T0nfLPZGLRrufEFCqqhrC41xJQlcl2txegJ
4wMAKCBFkiSenKd4iiZQk11EyZgTb5+EERReihImQFypVQaVOvxXv4a+0hlFWxgZ2sov8ESsiJQ/
nphwksqOfxus+gbk9M2bk2evT579fvL8+cmzX/OxtSlLbw8loan37qdv/nn5pff3bz++e/FtNvQy
Xpj4t7989faPP99nHma8CMXpd6/evn51+v3Xf/38wmF9h6OxCR+RGAvvLj72HrAYJujwH4/5xTRG
ESKmxk4SCpQgNYrDfl9GFvruHFHkwO1iO46POFCNC3hr9sRyeBjxmSQOi3ei2AIeMEZ3GXdG4Y4a
ywjzaJaE7sH5zMQ9QOjINXYXJVaW+7MUOJa4THYjbLl5n6JEohAnWHrqGTvE2DG7x4RYcT0gE84E
m0rvMfF2EXGGZETGVjUtlPZIDHmZuxyEfFuxOXjk7TLqmnUPH9lIeDcQdTg/wtQK4y00kyh2mRyh
mJoB30cycjk5nPOJiesLCZkOMWVeP8BCuHTucZivkfQ7QDPutB/QeWwjuSSHLpv7iDET2WOH3QjF
qQs7JElkYj8Xh1CiyLvPpAt+wOw3RN1DHlCyNt2PCLbSfTYbPASGNV1aFIh6MuOOXN7CzKrf4ZxO
EdZUAw3A4vWYJGeS/BK9N/87egcSPf3hpWNGV0PpbsNWPi5I5jucON+mvSUKX4dbJu4u4wH58Hm7
h2bJfQyvymrz+kjbH2nb/9/T9rr3+erJesHPQN1q2Zot1/XiPV67dp8SSodyTvG+0Mt3AV0pGIBQ
6ek9Ki73cmkEl+pNhgEsXMiR1vE4k18QGQ0jlMIav+orI6HITYfCS5mApb8WO20rPJ3FByzItqzV
qtqeZuQhkFzIK81SDtsNmaFb7cU2rDSvvQ31drlwQOlexAljMNuJusOJdiFUQdKbcwiawwk9syvx
YtPhxXVlvkjVihfgWpkVWDZ5sNjq+M0GqIAS7KoQxYHKU5bqIrs6mVeZ6XXBtCoA1hBFBSwyval8
XTs9Nbus1M6RacsJo9xsJ3RkdA8TEQpwXp1Keh43LprrzUVKLfdUKPR4UFoLN9rX3+fFZXMNesvc
QBOTKWjiHXf8Vr0JJTNBacefwtYfLuMUakeo5S6iIRyaTSTPXvjLMEvKhewhEWUB16STsUFMJOYe
JXHHV9Mv00ATzSHat2oNCOGDdW4TaOVDcw6SbicZT6d4Is20GxIV6ewWGD7jCudTrX55sNJkM0j3
MAqOvTGd8QcISqzZrqoABkTACVA1i2ZA4EizJLJF/S01ppx2zTNFXUOZHNE0QnlHMck8g2sqL93R
d2UMjLt8zhBQIyR5IxyHqsGaQbW6adk1Mh/Wdt2zlVTkDNJc9EyLVVTXdLOYNULRBpZiebkmb3hV
hBg4zezwGXUvU+5mwXVL64SyS0DAy/g5uu45GoLh2mIwyzXl8SoNK87OpXbvKCZ4hmvnaRIG67cK
s0txK3uEczgQXqrzg95y1YJoWqwrdaRdnycOUOqNw2rHh08EcDbxFK7gI4MPspqS1ZQMruDLAbSL
7Li/4+cXhQSeZ5ISUy8k9QLTKCSNQtIsJM1C0iokLd/T5+LwLUYdiftecewNPSw/Js/XFvY3nO1/
AQAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9f
cmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezb
G+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYp
JFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgU
nr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VI
lAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAI
AAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAI
AAAAIQDdDfsoIgMAAOAHAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJh
d2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAHaFahVWBgAADxoAABoAAAAAAAAAAAAAAAAAfwUAAGNs
aXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAA
AAAAAAAAAAAADQwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BL
BQYAAAAABQAFAGcBAAAQDQAAAAA=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>No. patients still at risk</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_2"
 o:spid="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
 margin-left:89.65pt;margin-top:149.15pt;width:121.85pt;height:32.9pt;
 z-index:251659264;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Censoring times</p><p>(a) Lu‑PSMA‑617+BSoC</p><p>(b) BSoC only</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_21" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:453.75pt;height:328.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="438" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Stratified log‑rank test and stratified Cox model using strata per Interactive Response Technology (IRT) defined by LDH level, presence of liver metastases, ECOG score and inclusion of an AR pathway inhibitor in BSoC at time of randomisation.</p><p>n/N: Number of events/number of patients in treatment arm.</p><p>&nbsp;</p><p><strong>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Kaplan‑Meier plot of BICR‑assessed rPFS in VISION</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1029" type="#_x0000_t202"
 style='position:absolute;margin-left:170pt;margin-top:309.7pt;width:158.75pt;
 height:13.4pt;z-index:251666432;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time from randomisation (months)</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1028" type="#_x0000_t202"
 style='position:absolute;margin-left:58.25pt;margin-top:257.5pt;width:121.8pt;
 height:11.55pt;z-index:251665408;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>No. patients still at risk</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;margin-left:280.75pt;margin-top:12pt;width:121.85pt;
 height:32.9pt;z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Censoring times</p><p>(a) Lu‑PSMA‑617+BSoC</p><p>(b) BSoC only</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t202"
 style='position:absolute;margin-left:6.6pt;margin-top:74.75pt;width:17.05pt;
 height:143.55pt;z-index:251663360;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
    lang=DE-CH style='font-size:9.0pt;mso-bidi-font-size:8.0pt;mso-ansi-language:
    DE-CH'>Event-free probability (%)</span><span lang=EN-GB style='font-size:
    9.0pt;mso-bidi-font-size:8.0pt'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--><img width="27" height="195" alt="Text Box: Event-free probability (%)" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /><!--[if gte vml 1]><v:shape id="Picture_x0020_20"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:453.75pt;height:328.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="438" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Stratified log‑rank test and stratified Cox model using strata per IRT defined by LDH level, presence of liver metastases, ECOG score and inclusion of an AR pathway inhibitor in BSoC at time of randomisation.</p><p>n/N: Number of events/number of patients in treatment arm.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Pluvicto in all subsets of the paediatric population in the treatment of PSMA‑expressing prostate cancer (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan have been characterised in 30&nbsp;patients in the phase&nbsp;III VISION sub‑study.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Pluvicto is administered intravenously and is immediately and completely bioavailable.</p><p>&nbsp;</p><p>The geometric mean blood exposure (area under the curve [AUC<sub>inf</sub>]) for lutetium (<sup>177</sup>Lu) vipivotide tetraxetan at the recommended dose is 52.3&nbsp;ng.h/mL (geometric mean coefficient of variation [CV] 31.4%). The geometric mean maximum blood concentration (C<sub>max</sub>) for lutetium (<sup>177</sup>Lu) vipivotide tetraxetan is 6.58&nbsp;ng/mL (CV 43.5%).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The geometric mean volume of distribution (V<sub>z</sub>) for lutetium (<sup>177</sup>Lu) vipivotide tetraxetan is 123&nbsp;L (CV 78.1%).</p><p>&nbsp;</p><p>Unlabelled vipivotide tetraxetan and non‑radioactive lutetium (<sup>175</sup>Lu) vipivotide tetraxetan are each 60% to 70% bound to human plasma proteins.</p><p>&nbsp;</p><p><u>Organ uptake</u></p><p>&nbsp;</p><p>The biodistribution of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan shows primary uptake in lacrimal glands, salivary glands, kidneys, urinary bladder wall, liver, small intestine and large intestine (left and right colon).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The geometric mean clearance (CL) for lutetium (<sup>177</sup>Lu) vipivotide tetraxetan is 2.04&nbsp;L/h (CV 31.5%).</p><p>&nbsp;</p><p>Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan is primarily eliminated renally.</p><p>&nbsp;</p><p><u>Half‑life</u></p><p>&nbsp;</p><p>Pluvicto shows a bi‑exponential elimination with a geometric mean terminal elimination half‑life (t<sub>&frac12;</sub>) of 41.6&nbsp;hours (CV 68.8%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan does not undergo hepatic or renal metabolism.</p><p>&nbsp;</p><p><em><u>In vitro</u></em><u> evaluation of drug interaction potential</u></p><p><em><u>&nbsp;</u></em></p><p><em><u>CYP450 enzymes</u></em></p><p>Vipivotide tetraxetan is not a substrate of cytochrome P450 (CYP450) enzymes. It does not induce cytochrome P450 (CYP) 1A2, 2B6 or 3A4, and it does not inhibit cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A4/5 <em>in vitro</em>.</p><p>&nbsp;</p><p><em><u>Transporters</u></em></p><p>Vipivotide tetraxetan is not a substrate of BCRP, P‑gp, MATE1, MATE2‑K, OAT1, OAT3 or OCT2, and it is not an inhibitor of BCRP, P‑gp, BSEP, MATE1, MATE2‑K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 or OCT2 <em>in vitro</em>.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em><u>Effects of age and body weight</u></em></p><p>No clinically significant effects on the pharmacokinetic parameters of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan were identified for the following covariates assessed in 30&nbsp;patients in the phase&nbsp;III VISION sub‑study: age (median: 67&nbsp;years; range: 52 to 80&nbsp;years) and body weight (median: 88.8&nbsp;kg; range: 63.8 to 143.0&nbsp;kg).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>Exposure (AUC) of lutetium (<sup>177</sup>Lu) vipivotide tetraxetan increased by 20% in patients with mild renal impairment compared to normal renal function. Kidney dosimetry half‑life also increased in patients with mild renal impairment compared to normal renal function, 51&nbsp;hours vs. 37&nbsp;hours, respectively. Patients with mild or moderate renal impairment may be at greater risk of toxicity (see section&nbsp;4.4). No pharmacokinetic data are available for patients with moderate to severe renal impairment with baseline CLcr &lt;50&nbsp;mL/min or end‑stage renal disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No toxicological effects were observed in safety pharmacology or single‑dose toxicity studies in rats and minipigs administered a non‑radioactive formulation containing unlabelled vipivotide tetraxetan and lutetium (<sup>175</sup>Lu) vipivotide tetraxetan, or in repeat‑dose toxicity studies in rats administered unlabelled vipivotide tetraxetan.</p><p>&nbsp;</p><p><u>Carcinogenicity and mutagenicity</u></p><p>&nbsp;</p><p>Mutagenicity and long‑term carcinogenicity studies have not been carried out with lutetium (<sup>177</sup>Lu) vipivotide tetraxetan; however, radiation is a carcinogen and mutagen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p>Acetic acid</p><p>Sodium acetate</p><p>Gentisic acid</p><p>Sodium ascorbate</p><p>Pentetic acid</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in sections&nbsp;4.2 and 12.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                120 hours (5 days) from the date and time of calibration.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not freeze.</p><p>Store in the original package in order to protect from ionising radiation (lead shielding).</p><p>&nbsp;</p><p>Storage of radiopharmaceuticals should be in accordance with national regulations on radioactive materials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear, colourless type&nbsp;I glass vial, closed with a bromobutyl rubber stopper and aluminium seal.</p><p>&nbsp;</p><p>Each vial contains a volume of solution that can range from 7.5&nbsp;mL to 12.5&nbsp;mL corresponding to a radioactivity of 7&nbsp;400&nbsp;MBq &plusmn;10% at the date and time of administration.</p><p>&nbsp;</p><p>The vial is enclosed within a lead container for protective shielding.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General warning</u></p><p>&nbsp;</p><p>Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.</p><p>&nbsp;</p><p>Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.</p><p>&nbsp;</p><p>For instructions on preparation of the medicinal product before administration, see section&nbsp;12.</p><p>&nbsp;</p><p>If at any time in the preparation of this medicinal product the integrity of the lead container or the vial is compromised it should not be used.</p><p>&nbsp;</p><p>Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.</p><p>&nbsp;</p><p>The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting, etc. Radiation protection precautions in accordance with national regulations must therefore be taken.</p><p>&nbsp;</p><p>This preparation is likely to result in a relatively high radiation dose to most patients. The administration of Pluvicto may result in significant environmental hazard. This may be of concern to the immediate family of those individuals undergoing treatment or the general public depending on the level of activity administered. Suitable precautions in accordance with national regulations should be taken concerning the activity eliminated by the patients in order to avoid any contaminations.</p><p>&nbsp;</p><p>Lutetium‑177 for Pluvicto may be prepared using two different sources of stable isotopes (either lutetium‑176 or ytterbium‑176). Lutetium‑177 for Pluvicto prepared using the stable isotope lutetium‑176 (&ldquo;carrier added&rdquo;) requires special attention with regard to waste management due to the presence of the long‑lived metastable lutetium‑177 (<sup>177m</sup>Lu) impurity with a half‑life of 160.4&nbsp;days. Lutetium‑177 for Pluvicto is prepared using ytterbium‑176 (&ldquo;non‑carrier added&rdquo;) unless otherwise communicated on the product batch release certificate. The user must consult the product batch release certificate provided before using Pluvicto to ensure appropriate waste management.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Europharm Limited.
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by EMA in Dec/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>